CClinicalTrials.gg
CompletedNCT06454994Updated Sep 11, 2026

Clinical Study to Evaluate Safety and Effectiveness of Noble Lift® Lifting Threads

An interventional study of Eyebrow lift and Jaw lift in Aesthetic, sponsored by GCS Co., Ltd. Completed at 4 sites in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by GCS Co., Ltd · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to compare two models of the Nobel Lift range (PDO sutures) with similar PDO devices available on the market, in a split-face comparative study. Each thread model will be used in one indication: upper face (eyebrow lift) or mid-face and lower-face.

Aesthetic efficacy of the devices will be evaluated and compared with the Global Aesthetic Improvement Scale (GAIS), jowl laxity scale, subjective evaluation of the patient and photographs during a 12-months period. Safety of the devices and procedures will also be evaluated.

02

Conditions studied

  • Aesthetic

Keywords

  • Lifting threads
  • Eyebrow lift
  • Jaw laxity
03

In context

Lead sponsor

GCS Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI comprised between 18.5 and 30
  • No ongoing or planned diet.
  • Group 1: requiring an aesthetic treatment of upper face with resorbable threads.
  • Group 2: Subject requiring an aesthetic treatment of mid-face and lower-face with resorbable threads
  • Subject with dense and not too thin skin.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing woman or planning a pregnancy during the study;
  • Suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study result and/or subject safety, especially cardiac disorder, non-controlled high blood pressure, diabetes, panic disorders, depression, active auto-immune disease, cold, high fever,…
  • Suffering from malnutrition.
  • Acute inflammatory process or infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events.
  • Wound healing disorder or with a disorder that may impact wound healing such as connective tissue or immunosuppressive disorder.
  • History of precancerous lesions/skin malignancies.
  • Active skin disease within 6 months of study entry.
  • Scars, rosacea, herpes, acne, blotches or other pathology in the face, at the investigator appreciation.
  • Predisposed to keloidosis or hypertrophic scarring.
  • Known history of hyper- or hypo-pigmentation in the face.
  • Known history of multiple allergies, allergic/anaphylactic reactions including allergy/ hypersensitivity to lidocaine, anaesthetics of the amide type, the used antiseptic components, the used antibiotic cream components.
  • Known bleeding disorder or is receiving medication that will likely increase the risk of bleeding during treatment.
  • Extensive skin laxity, thin skin and/or severe malar fat sagging.
  • Foreign body sensitivity or known or suspected allergies to implant or instrument materials in particular plastic/biomaterial.
  • Any medication which may interfere, at the interpretation of the investigator, with the study objectives in term of efficacy and safety/tolerance.
  • Dental care in the past 2 weeks or who planned to receive dental care in the 2 months after the treatment.
  • Anticoagulant (such as aspirin, warfarin, blood circulation enhancer and clotbuster) during the week before the injection session .
  • Chemotherapy agents, immunosuppressive medications or systemic corticosteroids in the past 3 months and during the study.
  • Lifting of the face in the past 12 months or other surgery of the face in the past 6 months.
  • Resorbable fillers within the past 12 months, other resorbable threads within the past 12 months, neurotoxin in the past 5 months or plans to receive such treatments during the study.
  • Permanent filler on the face.
  • Subcutaneous permanent retaining structure on the face (meshing, permanent threads, gold strand etc.).
  • Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Noble Lift threads

    Device: Eyebrow lift · Device: Jaw lift

  • Active comparator
    Croquis threads

    Device: Eyebrow lift · Device: Jaw lift

Interventions

  • DeviceEyebrow lift

    Upper face lifting

  • DeviceJaw lift

    Mid-face and low-face lifting

06

What researchers measure

Primary outcomes

  1. Comparison of Global Aesthetic Improvement (GAIS) by the investigator between both products

    Non-inferiority of Noble Lift® threads in comparison with Croquis® thread, in terms of GAIS mean score on Month 3, assessed by an independent blinded investigator on photos (in global and for each indication). GAIS is a scale from 1 (worse) to 5 (very much improved).

    Time frame: Month 3

Secondary outcomes

  1. Percentages of responders for Global Aesthetic Improvement (GAIS) by the investigator

    GAIS is a scale from 1 (worse) to 5 (very much improved)

    Time frame: Month 3, Month 6, Month 12

  2. Percentages of responders for Global Aesthetic Improvement (GAIS) by the subject

    GAIS is a scale from 1 (worse) to 5 (very much improved)

    Time frame: Month 3, Month 6, Month 12

  3. Change from baseline of Facial Laxity Rating Scale (FLRS) score

    FLRS is a scale from 1 (mild laxity) to 9 (severe laxity)

    Time frame: Month 3, Month 6, Month 12

  4. Percentages of subjects satisfied with the intervention using a subjective evaluation questionnaire

    Answers are evaluated from 1 (very dissatisfied) to 5 (very satisfied)

    Time frame: Month 3, Month 6, Month 12

  5. Number and percentages of immediate and early skin reactions collected by the subject

    Skin reactions are scored as mild, moderate or severe

    Time frame: Month 1

  6. Number and percentages of skin reactions scored by the investigator

    Skin reactions are scored as mild, moderate or severe

    Time frame: Month1, Month 3, Month 6, Month 12

  7. Number and percentages of Adverse Events

    Time frame: Month1, Month 3, Month 6, Month 12

07

Study locations

4 sites
  • Dr Jeanblanc
    Aix-en-Provence, France
  • Dr Facchinetti
    Cannes, France
  • Dr Converset-Viethel
    Lyon, France
  • Dr Lemmel
    Paris, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06454994
Lead sponsor
GCS Co., Ltd
Collaborators
Eurofins Laboratoire Dermscan
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Jun 5, 2024
Primary completion
May 24, 2025
Completion
Feb 24, 2026
Last update
Sep 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion